Trifluoperazine, an orally available clinically used drug, disrupts opioid antinociceptive tolerance
Authors:
- Pradeep K. ShuklaPSPradeep K. Shukla
- Zaijie Jim WangZWZaijie Jim Wang
- 1 April 2006
- journal article
- research article
- Published by Elsevier in Neuroscience Letters
- Vol. 397 (1-2) , 1-4
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Neuronal Ca2+/Calmodulin-Dependent Protein Kinase II: The Role of Structure and Autoregulation in Cellular FunctionAnnual Review of Biochemistry, 2002
- Differential Effects of μ-Opioid Receptor Ligands on Ca2+ SignalingThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Reduced development of tolerance to the analgesic effects of morphine and clonidine in PKCγ mutant micePain, 2001
- Involvement of phospholipid signal transduction pathways in morphine tolerance in miceBritish Journal of Pharmacology, 1999
- Site Mutation in the Rat μ‐Opioid Receptor Demonstrates the Involvement of Calcium/Calmodulin‐Dependent Protein Kinase II in Agonist‐Mediated DesensitizationJournal of Neurochemistry, 1997
- The effects of recombinant rat μ‐opioid receptor activation in CHO cells on phospholipase C, [Ca2+]i and adenylyl cyclaseBritish Journal of Pharmacology, 1997
- Mechanisms of hyperalgesian and morphine tolerance: a current view of their possible interactionsPain, 1995
- Accelerated communciation: Constitutive μ opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependenceLife Sciences, 1994
- Pharmacological antagonism of calmodulinCanadian Journal of Biochemistry and Cell Biology, 1983
- Differential effects on mouse brain catecholamine turnover of chlorpromazine, trifluoperazine and closely-related non-tranquillizing analoguesJournal of Pharmacy and Pharmacology, 1973